Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ALN-CIDEB

Oligonucleotide (siRNA) · Gene silencing: CIDEB · developed by Regeneron Pharmaceuticals

Phase 3 Most advanced trial
REGN Developer
1 Registered trials

What is ALN-CIDEB?

ALN-CIDEB is an siRNA-based agent that acts on CIDEB, the gene encoding cell death-inducing DFFA-like effector B, to lower its expression. It is being studied in metabolic dysfunction-associated steatotic liver disease (MASLD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
CIDEB
Mechanism
Gene silencing: CIDEB
Therapy area
Gastroenterology
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07854782 Phase 3 Metabolic Dysfunction-Associated Steatotic Liver Disease Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MASLDMetabolic Dysfunction-Associated Steatotic Liver Disease

More from Regeneron Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind ALN-CIDEB

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.